Search results for " heart"

showing 10 items of 741 documents

Treatment and Prophylaxis

1991

Following a stroke, the patient’s neurologic deficit may be most impressive, but his treatment and prognosis depend largely upon accompanying systemic disorders. Acute treatment, for instance, must take into consideration such things as cardiovascular disorders (myocardial infarction, valve defects, arrhythmias, hypertension), disorders of renal function, and diabetes mellitus. The early detection and treatment of such systemic problems can help to prevent complications that would be difficult to control later. Thus, in a patient with latent heart disease hypervolemic therapy with low molecular weight dextran may in fact elicit right heart failure and pulmonary edema instead of helping the …

medicine.medical_specialtyHeart diseasebusiness.industryCerebral infarctionRenal functionmedicine.diseasePulmonary edemaLow molecular weight dextranRight heart failureDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionbusiness
researchProduct

Giant left atrium: a condition that is rarely seen today.

2008

Today, giant left atrium is a condition that is rarely observed in clinical practice and diagnosis can be missed. It is prevalent in patients with rheumatic heart disease that has decreased considerably in industrialized countries in the last two decades. However, the immigration flow in the current era can revive its incidence.

medicine.medical_specialtyHeart diseasebusiness.industryGeneral surgeryIncidence (epidemiology)fungiRheumatic Heart Diseasefood and beveragesCardiomegalyGeneral MedicineMiddle AgedGiant left atriummedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareClinical PracticeMedicineHumansIn patientFemaleHeart AtriaCardiology and Cardiovascular MedicinebusinessGiant left atriumJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Home is the new gym: exergame as a potential tool to maintain adequate fitness levels also during quarantine

2020

Purpose With the coronavirus outbreak, the preventive measures include staying at home and isolation, increasing sedentary behaviours and risk for worsening of chronic diseases To explore alternative forms of home-based physical activity, the study aim was to evaluate physiological (heart rate [HR], respiratory exchange ratio [RER], oxygen consumption [ O2], energy expenditure [EE], metabolic equivalent task [MET]) and psychological (session rating of perceived exertion [sRPE], enjoyment) parameters of real (Zumba® class [ZC]) and exergame (Zumba® Fitness Rush [ZFR]) activities in relation to sex Methods Overall, 12 female (age: 24 7 ± 0 9 years) and 8 male (age: 25 3 ± 2 1 years) college s…

medicine.medical_specialtyHeart rateBiophysicsPhysical activityOxygen consumption030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationMetabolic equivalentZumba03 medical and health sciences0302 clinical medicineHeart ratemedicineRespiratory exchange ratioCOVID-19 Energy expenditure Heart rate Home training Oxygen consumption ZumbaRating of perceived exertionHome environmentHome trainingbusiness.industryCOVID-19; Energy expenditure; Heart rate; Home training; Oxygen consumption; ZumbaPublic Health Environmental and Occupational HealthCOVID-19030229 sport sciencesEnergy expenditureGV557-1198.995Physical therapyExercise intensityEnergy expenditurebusinessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieSportsHuman Movement
researchProduct

Lysosomal trafficking in rat cardiac myocytes.

1990

By immunolabeling of cryosections, we have characterized in rat cardiac myocytes the cation-independent mannose-6-phosphate receptor (MPR), a lysosomal membrane glycoprotein, lgp120, and a lysosomal enzyme, MEP (homologous to cathepsin L). Most of the MPR label was located in large membrane-filled structures (MPR structures) in large clusters of mitochondria adjacent to but distinct from the Golgi complex. Lpg120 and MEP showed typical lysosomal localization throughout the cell, often associated with regions that appeared to contain autophagosome-like structures. In addition, MEP and lgp120 co-localized within MPR structures. MEP and MPR were localized inside the lumen of MPR structures. M…

medicine.medical_specialtyHistologyCathepsin LImmunoblottingFluorescent Antibody TechniqueReceptors Cell SurfaceMitochondrionMitochondria HeartReceptor IGF Type 2Cathepsin LImmunolabelingsymbols.namesakeAntigens CDLysosomal-Associated Membrane Protein 1Internal medicineLysosomeEndopeptidasesmedicineAnimalsFrozen SectionsMyocyteReceptorchemistry.chemical_classificationMembrane GlycoproteinsbiologyMyocardiumLysosome-Associated Membrane GlycoproteinsIntracellular MembranesGolgi apparatusCathepsinsRatsCell biologyCysteine EndopeptidasesMicroscopy ElectronEndocrinologymedicine.anatomical_structureAnimals NewbornLiverchemistrybiology.proteinsymbolsCattleAnatomyLysosomesGlycoproteinJournal of Histochemistry & Cytochemistry
researchProduct

Selenoprotein synthesis and side-effects of statins.

2004

Statins are possibly the most effective drugs for the prevention and treatment of hypercholesterolaemia and coronary heart disease. They are generally well tolerated, however, they do cause some unusual side-effects with potentially severe consequences, most prominently myopathy or rhabdomyolysis and polyneuropathy. We noted that the pattern of side-effects associated with statins resembles the pathology of selenium deficiency, and postulated that the mechanism lay in a well established, but often overlooked, biochemical pathway--the isopentenylation of selenocysteine-tRNA([Ser]Sec). A negative effect of statins on selenoprotein synthesis does seem to explain many of the enigmatic effects a…

medicine.medical_specialtyHypercholesterolemiaCoronary DiseaseBioinformaticsModels BiologicalRhabdomyolysisPolyneuropathiesSeleniumMuscular DiseasesSelenium deficiencyInternal medicinemedicineHumanscardiovascular diseasesSelenium metabolismMyopathySelenoproteinschemistry.chemical_classificationbusiness.industrynutritional and metabolic diseasesProteinsGeneral Medicinemedicine.diseaseCoronary heart diseaseEndocrinologychemistryProteins metabolismProtein Biosynthesislipids (amino acids peptides and proteins)Selenoproteinmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRhabdomyolysisPolyneuropathyLancet (London, England)
researchProduct

Tocilizumab therapy for unresponsive pulmonary arterial hypertension in a patient with Takayasu arteritis

2016

A 46-year-old female Caucasian patient was referred to our unit with upper extremity claudication, dyspnoea [New York Heart Association (NYHA) Class III], and weight loss. On physical examination, ...

medicine.medical_specialtyHypertension PulmonaryAntibodieTakayasu arteritisImmunologyPhysical examinationClass iiiTakayasu ArteritiAntibodies Monoclonal HumanizedTocilizumab therapyNew york heart association03 medical and health sciences0302 clinical medicineAntibodies Monoclonal Humanized; Female; Humans; Hypertension Pulmonary; Middle Aged; Takayasu Arteritis; Immunology and Allergy; Rheumatology; Immunology; Medicine (all)RheumatologyWeight lossInternal medicineMonoclonalmedicineImmunology and AllergyHumanized030203 arthritis & rheumatologymedicine.diagnostic_testbusiness.industryMedicine (all)General MedicinePulmonaryMiddle Agedmedicine.diseasePulmonary hypertensionSettore MED/16 - ReumatologiaHypertensionCardiologyFemalemedicine.symptomClaudicationbusiness030217 neurology & neurosurgeryHuman
researchProduct

Cardiovascular comorbidity in multiple sclerosis patients treated with mitoxantrone therapy: a cohort study

2017

Abstract Background Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS). Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered relatively safe. We calculated the frequency of cardiac side effects in MS patients treated with MX. Methods We performed a cohort study including all MS patients treated with MX at the Neurological Department of the University Hospital of Palermo, Italy. Two hundred-sixty-four MS patients diagnosed according to validated criteria were included and followed-up until the end of September 2010. Patients were treated with MX as a second line therapy if they had no prev…

medicine.medical_specialtyImmunologyHeart failureComorbidity030204 cardiovascular system & hematologylcsh:RC346-429Multiple sclerosis03 medical and health sciences0302 clinical medicineInternal medicinemedicineImmunology and AllergyMyocardial infarctionlcsh:Neurology. Diseases of the nervous systemMitoxantroneEjection fractionmedicine.diagnostic_testCumulative dosebusiness.industryComorbidity Multiple sclerosis Heart failure Mitoxantrone Therapymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareNeurologyHeart failureCohortPhysical therapySettore MED/26 - NeurologiaTherapyNeurology (clinical)MitoxantronebusinessElectrocardiography030217 neurology & neurosurgeryCohort studymedicine.drug
researchProduct

Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness

2018

The aim of this case report is to assess the potential role of intrarenal Doppler ultrasonography as a non‐invasive method to evaluate intrarenal venous flow (IRVF) in acute heart failure (AHF) and concomitant renal dysfunction. We report a case of an 81‐year‐old woman with valvular heart disease (previous mitral valve replacement) that presented with acutely decompensated heart failure and concomitant worsening renal function (WRF). In addition to complete physical examination, laboratory analysis, and echocardiography, IRVF was assessed at baseline and 48 h after the administration of diuretic treatment. At admission, physical examination and echocardiography revealed signs of intravascul…

medicine.medical_specialtyKidneyCreatininebusiness.industrymedicine.medical_treatmentvalvular heart diseaseMitral valve replacementRenal functionCardiorenal syndrome030204 cardiovascular system & hematologymedicine.diseaseInferior vena cava03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicine.anatomical_structuremedicine.veinchemistryHeart failureInternal medicinemedicineCardiology030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction

2019

Aim: To evaluate the long-term outcome of patients with Takotsubo syndrome (TTS) and severely reduced left ventricular ejection fraction (LVEF ≤ 35%) at presentation. Methods and results: The study population included 326 patients (mean age 69.5 ± 10.7 years, 28 male) with TTS enrolled in the Takotsubo Italian Network, divided into two groups according to LVEF (≤ 35%, n = 131; > 35%, n = 195), as assessed by transthoracic echocardiography at hospital admission. In-hospital events were recorded in both groups. At long-term follow-up (median 26.5 months, interquartile range 18–33), composite major adverse cardiac events (MACE: cardiac death, acute myocardial infarction, heart failure, and …

medicine.medical_specialtyLeft ventricular ejection fractionCardiomyopathyHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecardiovascular diseasesMyocardial infarctionCardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndromeCardiogenic shockEjection fractionbusiness.industryCardiogenic shockHazard ratiomedicine.diseaseConfidence intervalHeart failureCardiologybusinessTakotsubo syndromeCardiology and Cardiovascular MedicineCardiogenic shock; Cardiomyopathy; Heart failure; Left ventricular ejection fraction; Takotsubo syndrome; Cardiology and Cardiovascular MedicineMace
researchProduct

Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA(1-64)) in the rat heart

2010

Cytoskeleton scaffold in cardiac myocytes provides structural support and compartmentalization of intracellular components. It is implicated in cardiac pathologies including hypertrophy and failure, playing a key role in the determinism of contractile and diastolic dysfunctions. Chromogranin A (CgA) and its derived peptides have revealed themselves as novel cardiovascular modulators. In humans, normal CgA levels considerably increase in several pathologies, including heart failure. Recent data have shown on the unstimulated rat heart that human recombinant Vasostatin-1 (hrVS-1) and rat chromogranin A 1-64 (rCgA(1-64)) induce negative inotropic and lusitropic effects counteracting the beta-a…

medicine.medical_specialtyMESH: RatsPhysiologyPhalloidin[SDV]Life Sciences [q-bio]Clinical BiochemistryMESH: Myocytes Cardiacmacromolecular substancesBiologyBiochemistryWortmanninCellular and Molecular Neurosciencechemistry.chemical_compoundEndocrinologyInternal medicineMyosinmedicineMESH: CytoskeletonMyocyteMESH: AnimalsCytoskeletonActinMESH: In Vitro TechniquesMESH: HumansSettore BIO/16 - Anatomia UmanaChromogranin AMESH: Rats WistarMESH: MaleCell biologyMESH: Cell LineMESH: Heart[SDV] Life Sciences [q-bio]EndocrinologychemistryInotropismVasostatin Rat CgA1-64 Rat Langendorff heart Inotropy Lusitropy Cardiomyocytes Cytoskeletonbiology.proteinMESH: Chromogranin A
researchProduct